Clinical Trials Logo

Filter by:
NCT ID: NCT06060704 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Start date: November 2023
Phase: Phase 2
Study type: Interventional

The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or intolerant to standard therapy.

NCT ID: NCT06060132 Recruiting - Cardiotoxicity Clinical Trials

Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection

Start date: January 29, 2023
Phase:
Study type: Observational

To study the current status of cardiotoxicity of arsenious acid by analyzing the literature, monitoring data, and real-world applications, and to discuss risk factors and preventive and control measures.

NCT ID: NCT06060080 Recruiting - Multiple Myeloma Clinical Trials

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Start date: April 22, 2022
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness and safety of PEG-rhG-CSF injection for the reconstruction of neutrophil cells after autologous hematopoietic stem cell transplantation in lymphoma/multiple myeloma patients.

NCT ID: NCT06059885 Recruiting - Liver Neoplasms Clinical Trials

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Start date: December 22, 2021
Phase: Phase 2
Study type: Interventional

Background: Ablation is important radical treatment in hepatocellular carcinoma (HCC). However, the 5-year recurrence rate of HCC after ablation is up to 80%. Early and late recurrences are more likely related to tumor size, tumor multiplicity, vascular invasion, higher serum AFP level and disease etiology, etc. Some studies suggested that adjuvant immunotherapy might be associated with decreased recurrence and prolonged RFS. Adjuvant atezolizumab + bevacizumab (IMbrave 050) showed RFS improvement following curative resection or ablation. Currently, there is limited study on immunotherapy combined with TKI as postoperative adjuvant therapy for HCC. This is an open-label, prospective cohort study to compare the efficacy and safety of tislelizumab plus tyrosine kinase inhibitor (TKI) as adjuvant therapy versus active surveillance in HCC patients with high risk of recurrence after curative ablation.

NCT ID: NCT06059573 Recruiting - Dental Implant Clinical Trials

The Accuracy of Dental Implant Placement Using Robotic System-assisted Surgery and Freehand Surgery

Start date: October 7, 2023
Phase: N/A
Study type: Interventional

We plan to conduct this randomized clinical trial to compare the implant positional accuracy of robotic system-assisted implant surgery with that of conventional freehand implant surgery. Patients will be enrolled and randomly assigned to either an experimental group that underwent robotic surgery or a control group that underwent freehand surgery, to evaluate the accuracy of implant in both groups.

NCT ID: NCT06059560 Recruiting - Cancer Clinical Trials

Nutritional Intervention for Patients With Multiple Cancer Types

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the nutritional status of patients with different types of tumors by continuous nutritional intervention and follow-up intervention in the perioperative period,and the impact on progression-free survival/survival and quality of life.

NCT ID: NCT06059521 Recruiting - Myopia Clinical Trials

Software Refraction With Mobilerone Versus Retinoscopy

SRMR
Start date: July 15, 2023
Phase: N/A
Study type: Interventional

Software refraction in the mobilerone for myopia and astigmatism is a novel medical device for myopia adults and elder children with or without astigmatism. And the investigators would like to test its accuracy and efficacy as well as safety.

NCT ID: NCT06059508 Recruiting - Clinical trials for Advanced Malignant Tumor

Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors

Start date: October 25, 2023
Phase: Phase 1
Study type: Interventional

This study is an open, multicenter, dose-increasing/dose-expanding/efficacy expanding Phase I clinical study aimed at evaluating the tolerance, safety, PK, PD, and immunogenicity of SHR-5495 in the treatment of advanced malignant tumor patients, and preliminarily observing its anti-tumor efficacy. The entire study was divided into three stages: dose escalation, dose extension, and efficacy extension.

NCT ID: NCT06059248 Recruiting - General Anesthesia Clinical Trials

Effect of Different Head Positions During Endotracheal Intubation on Postoperative Sore Throat

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this [ randomized clinical trial] is to [effect of different head positions on the incidence of postoperative sore throat ] in [patients with endotracheal intubation ]. The main question it aims to answer is: the rate of postoperative sore throat will be reduced or not with the patients' head position changed during intubation.

NCT ID: NCT06058130 Recruiting - Atrial Fibrillation Clinical Trials

Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis

ALLY
Start date: September 29, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the safety and effectiveness of anticoagulation combined with antiplatelet therapy in acute ischemic stroke (AIS) patients with concomitant non-valvular atrial fibrillation (NVAF) and extracranial/intracranial artery stenosis. Participants will be 1:1 randomized into anticoagulation alone or anticoagulation combined with antiplatelet therapy. The primary endpoint is composite events 3 months after enrollment.